Voloridge Investment Management LLC Lowers Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)

Voloridge Investment Management LLC trimmed its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 49.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 87,513 shares of the biotechnology company's stock after selling 85,708 shares during the quarter. Voloridge Investment Management LLC owned approximately 0.29% of AnaptysBio worth $1,159,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Tower Research Capital LLC TRC grew its holdings in shares of AnaptysBio by 131.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 1,531 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in AnaptysBio during the 4th quarter valued at $40,000. AlphaQuest LLC boosted its position in AnaptysBio by 1,891.5% during the 4th quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock valued at $59,000 after buying an additional 4,237 shares during the period. Virtus ETF Advisers LLC grew its holdings in AnaptysBio by 24.7% in the 4th quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company's stock worth $63,000 after acquiring an additional 936 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its position in shares of AnaptysBio by 1,585.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,698 shares of the biotechnology company's stock valued at $75,000 after acquiring an additional 5,360 shares during the period.

Analyst Ratings Changes

ANAB has been the subject of a number of analyst reports. Wolfe Research assumed coverage on shares of AnaptysBio in a report on Tuesday, February 4th. They set an "outperform" rating and a $25.00 target price for the company. Wells Fargo & Company increased their price objective on AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Johnson Rice reiterated a "buy" rating on shares of AnaptysBio in a research report on Wednesday, March 26th. HC Wainwright restated a "neutral" rating and set a $22.00 target price on shares of AnaptysBio in a report on Tuesday, March 4th. Finally, JPMorgan Chase & Co. raised their price target on AnaptysBio from $36.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, AnaptysBio presently has an average rating of "Moderate Buy" and an average price target of $40.38.

AnaptysBio Stock Performance

Shares of ANAB traded down $0.37 on Monday, reaching $21.86. The stock had a trading volume of 666,792 shares, compared to its average volume of 614,203. AnaptysBio, Inc. has a 12-month low of $12.21 and a 12-month high of $41.31. The firm has a market capitalization of $642.25 million, a price-to-earnings ratio of -3.60 and a beta of -0.20. The company has a 50-day simple moving average of $19.80 and a 200-day simple moving average of $18.25.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.30) by $0.02. The business had revenue of $27.77 million during the quarter, compared to the consensus estimate of $15.27 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. On average, analysts expect that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio declared that its Board of Directors has initiated a share repurchase plan on Monday, March 24th that allows the company to buyback $75.00 million in shares. This buyback authorization allows the biotechnology company to repurchase up to 13.1% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's board of directors believes its stock is undervalued.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.